Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial.
暂无分享,去创建一个
George Starkschall | K. | Alan Pollack | Eugene Huang | D. Kuban | I. Rosen | J. Lee | G. Starkschall | A. V. von Eschenbach | J. Antolak | A. Pollack | E. Huang | G. Zagars | Deborah A Kuban | J Jack Lee | Gunar K Zagars | John A Antolak | Deborah | Andrew C von Eschenbach | Isaac Rosen | A. C. Eschenbach | I. Rosen | C. | von Eschenbach | A. | J. | J. Lee | J. Lee | Gunar | Zagars | John | Andrew | Antolak | Jack Lee | Kuban | Alan Pollack | J.Jack Lee | Deborah | John | Antolak | Jack Lee | Andrew | Von Eschenbach | Kuban
[1] E. Feuer,et al. Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. , 1999, Journal of the National Cancer Institute.
[2] P. Walsh,et al. Cancer surveillance series: interpreting trends in prostate cancer--part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. , 2000, The Journal of urology.
[3] D. Dearnaley,et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial , 1999, The Lancet.
[4] T. Pajak,et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.
[5] C. Perez,et al. Irradiation of carcinoma of the prostate localized to the pelvis: analysis of tumor response and prognosis. , 1980, International journal of radiation oncology, biology, physics.
[6] A. V. von Eschenbach,et al. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. , 2000, International journal of radiation oncology, biology, physics.
[7] D. Bostwick,et al. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. , 1998, Mayo Clinic proceedings.
[8] G Starkschall,et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Americansocietyfortherapeuticr. Consensus statement: Guidelines for PSA following radiation therapy1 , 1997 .
[10] T E Schultheiss,et al. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. , 1999, The cancer journal from Scientific American.
[11] P. Maingon,et al. Dose escalation with 3D-CRT in prostate cancer: French study of dose escalation with conformal 3D radiotherapy in prostate cancer-preliminary results. , 2000, International journal of radiation oncology, biology, physics.
[12] M M Urie,et al. Conformal irradiation of the prostate: estimating long-term rectal bleeding risk using dose-volume histograms. , 1996, International journal of radiation oncology, biology, physics.
[13] E. K. Harris,et al. Survivorship Analysis for Clinical Studies , 1990 .
[14] T E Schultheiss,et al. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. , 1998, International journal of radiation oncology, biology, physics.
[15] A Pollack,et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. , 2000, International journal of radiation oncology, biology, physics.
[16] G E Hanks,et al. Patterns of care studies: dose-response observations for local control of adenocarcinoma of the prostate. , 1985, International journal of radiation oncology, biology, physics.
[17] E. Crawford,et al. Advanced prostate cancer , 1999, Prostate Cancer and Prostatic Diseases.
[18] H. Levin,et al. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Hanlon,et al. Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales. , 1997, International journal of radiation oncology, biology, physics.
[20] A. Pollack,et al. External beam radiotherapy for stage T1/T2 prostate cancer: how does it stack up? , 1998, Urology.
[21] C. Reddy,et al. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. , 2000, Urology.
[22] G E Hanks,et al. The effect of dose on local control of prostate cancer. , 1988, International journal of radiation oncology, biology, physics.
[23] C. Perez,et al. Definitive radiation therapy in carcinoma of the prostate localized to the pelvis: experience at the Mallinckrodt Institute of Radiology. , 1988, NCI monographs : a publication of the National Cancer Institute.
[24] A. Hanlon,et al. Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/mL prostate cancer. , 2000, International journal of radiation oncology, biology, physics.
[25] A. Pollack,et al. Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. , 1998, Urology.
[26] A. Pollack,et al. External beam radiotherapy dose response of prostate cancer. , 1997, International journal of radiation oncology, biology, physics.
[27] J. Forman. Does pelvic irradiation play a role in the management of prostate cancer , 1998 .
[28] C. Reddy,et al. Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10). , 2001, International journal of radiation oncology, biology, physics.
[29] Christopher U. Jones,et al. A phase III trial comparing whole-pelvic (WP) to prostate only (PO) radiotherapy and neoadjuvant to adjuvant total androgen suppression (TAS): preliminary analysis of RTOG 9413 , 2001 .
[30] H. Bartelink,et al. LATE EFFECTS TOXICITY SCORING : THE SOMA SCALE , 1995 .
[31] A. Markoe,et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. , 2000, International journal of radiation oncology, biology, physics.
[32] S L George,et al. Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome [corrected]. , 1993, Controlled clinical trials.
[33] C C Ling,et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. , 2001, The Journal of urology.
[34] T E Schultheiss,et al. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect. , 1996, International journal of radiation oncology, biology, physics.
[35] D. Cox,et al. Analysis of Survival Data. , 1986 .
[36] M. Roach,et al. Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer. , 1998, International journal of radiation oncology, biology, physics.
[37] L. Verhey,et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. , 1995, International journal of radiation oncology, biology, physics.
[38] A. Zietman,et al. Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. , 2002, The Journal of urology.